News coverage about DURECT Corporation (NASDAQ:DRRX) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DURECT Corporation earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 47.0333134594744 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment’s analysis:

Shares of DURECT Corporation (NASDAQ:DRRX) opened at 1.63 on Friday. The company’s 50 day moving average is $1.70 and its 200-day moving average is $1.23. The stock’s market capitalization is $239.61 million. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $1.92.

DURECT Corporation (NASDAQ:DRRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.02. The business had revenue of $4.32 million during the quarter, compared to analysts’ expectations of $5.17 million. DURECT Corporation had a negative return on equity of 629.35% and a negative net margin of 221.01%. On average, equities analysts predict that DURECT Corporation will post ($0.21) earnings per share for the current year.

A number of analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of DURECT Corporation in a research note on Monday, May 22nd. Stifel Nicolaus upgraded shares of DURECT Corporation from a “hold” rating to a “buy” rating and upped their price target for the company from $1.25 to $3.00 in a research note on Wednesday, July 12th.

WARNING: “DURECT Corporation (DRRX) Earns Daily Media Sentiment Score of 0.12” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/20/durect-corporation-drrx-earns-daily-media-sentiment-score-of-0-12.html.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT Corporation (NASDAQ:DRRX)

Receive News & Stock Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related stocks with our FREE daily email newsletter.